Maurits F J M Vissers

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Venues

Clinical and translational science

Movement disorders : official journal of the Movement Disorder Society

British journal of clinical pharmacology

Nature medicine

Centre for Human Drug Research

Rijksuniversiteit Groningen (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Centre for Human Drug Research Sep 01 2018

Netherlands

Clinical Scientist :: CNS

AbbVie Inc Mar 01 2016 - Sep 01 2018

Netherlands

MSL :: Medical Affairs

Education History

Rijksuniversiteit Groningen

Netherlands

MSC :: Pharmacy

Publications

Pepijn Eijsvogel, Pinaki Misra, Luis Concha-Marambio, Justin D Boyd, Shuang Ding, Lauren Fedor, Yueh-Ting Hsieh, Yu Shuang Sun, Madeline M Vroom, Carly M Farris, Yihua Ma, Marieke L de Kam, Igor Radanovic, Maurits F J M Vissers, Dario Mirski, Ghazal Shareghi, Mohammad Shahnawaz, Wolfgang Singer, Philip H C Kremer, Geert Jan Groeneveld, Hui Jing Yu, Jean-Cosme Dodart
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial. Nature medicine (2024)
Maurits F J M Vissers, Matthew D Troyer, Eva Thijssen, Jules A A C Heuberger, Geert Jan Groeneveld, Sarah Huntwork-Rodriguez
A Leucine-Rich Repeat Kinase 2 (LRRK2) Pathway Biomarker Characterization Study in Patients with Parkinson's Disease with and without LRRK2 Mutations and Healthy Controls. Clinical and translational science (2023)
Danna Jennings, Sarah Huntwork-Rodriguez, Maurits F J M Vissers, Vinay M Daryani, Dolores Diaz, Marisa S Goo, John J Chen, Romeo D Maciuca, Kyle Fraser, Omar S Mabrouk, Jeroen van de Wetering de Rooij, Jules A A C Heuberger, Geert Jan Groeneveld, Marie T Borin, Andrés Cruz-Herranz, Danielle Graham, Kimberly A Scearce-Levie, Javier De Vicente, Anastasia G Henry, Peter Chin, Carole Ho, Matthew D Troyer
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society (2023)
Danna Jennings, Sarah Huntwork-Rodriguez, Maurits F J M Vissers, Vinay M Daryani, Dolores Diaz, Marisa S Goo, John J Chen, Romeo D Maciuca, Kyle Fraser, Omar S Mabrouk, Jeroen van de Wetering de Rooij, Jules A A C Heuberger, Geert Jan Groeneveld, Marie T Borin, Andrés Cruz-Herranz, Danielle Graham, Kimberly A Scearce-Levie, Javier De Vicente, Anastasia G Henry, Peter Chin, Carole Ho, Matthew D Troyer
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society 38 (3) (2023)
Danna Jennings, Sarah Huntwork-Rodriguez, Maurits F J M Vissers, Vinay M Daryani, Dolores Diaz, Marisa S Goo, John J Chen, Romeo D Maciuca, Kyle Fraser, Omar S Mabrouk, Jeroen van de Wetering de Rooij, Jules A A C Heuberger, Geert Jan Groeneveld, Marie T Borin, Andrés Cruz-Herranz, Danielle Graham, Kimberly A Scearce-Levie, Javier De Vicente, Anastasia G Henry, Peter Chin, Carole Ho, Matthew D Troyer
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society 38 (3) (2023)
Maurits F J M Vissers, Matthew D Troyer, Eva Thijssen, Jules A A C Heuberger, Geert Jan Groeneveld, Sarah Huntwork-Rodriguez
A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls. Clinical and translational science (2023)
Maurits F J M Vissers, Jules A A C Heuberger, Geert Jan Groeneveld, Jerome Oude Nijhuis, Peter Paul De Deyn, Salah Hadi, Jeffrey Harris, Richard M Tsai, Andres Cruz-Herranz, Fen Huang, Vincent Tong, Rebecca Erickson, Yuda Zhu, Kimberly Scearce-Levie, Jennifer Hsiao-Nakamoto, Xinyan Tang, Megan Chang, Brian M Fox, Anthony A Estrada, Robert J Pomponio, Miguel Alonso-Alonso, Moshe Zilberstein, Nazem Atassi, Matthew D Troyer, Carole Ho
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients. Clinical and translational science 15 (8) (2022)
Manon L M Prins, Johan L van der Plas, Maurits F J M Vissers, Cécile L Berends, Gaby Tresch, Marianne Soergel, Elena Fernández, Nikita van den Berge, Daniël Duijsings, Christof Zitt, Vaia Stavropoulou, Maya Zimmermann, Roxana F Drake, Jacobus Burggraaf, Geert H Groeneveld, Ingrid M C Kamerling
Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study. British journal of clinical pharmacology (2022)
Maurits F J M Vissers, Jules A A C Heuberger, Geert Jan Groeneveld
Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders. International journal of molecular sciences 22 (4) (2021)
Maurits F J M Vissers, Adam F Cohen, Joop M A Van Gerven, Geert Jan Groeneveld
The impact of the global COVID-19 pandemic on the conduct of clinical trials: Return to normalcy by considering the practical impact of a structured ethical analysis. British journal of clinical pharmacology 87 (3) (2020)

Maurits F J M Vissers.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Maurits F J M Vissers